Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novo Nordisk Will Add Jobs In U.S.

by Lisa M. Jarvis
May 7, 2012 | A version of this story appeared in Volume 90, Issue 19

Danish drug firm Novo Nordisk plans to increase its U.S. workforce, now 4,100, by 15% in 2012. Sales positions will represent much of the growth in headcount, but the company says it is also recruiting scientists for its new type 1 diabetes R&D site in Seattle and workers for its manufacturing facility in Clayton, N.C. In separate news, Novo Nordisk has licensed heparosan-based drug delivery technology from Oklahoma City-based Caisson Biotech. The deal could be worth more than $100 million in milestone payments, Caisson says, if drugs using its technology reach the market.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.